NCT02964195

Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Bleeding

Efficacy of Rifaximin in Treatment of Cirrhotic Gastroesophageal Variceal Hemorrhage: A Multi-center Randomized Controlled Clinical Trial

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 308 (estimated)
• Sponsor: Shanghai Zhongshan Hospital · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The purpose of the study is to evaluate the efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

Detailed description

Gastroesophageal variceal bleeding is the most common and life-threatening condition in patients with portal hypertension, which are susceptibility to bacterial infection. However, the prophylaxis use of antibiotics remained uncertain and lack of high level evidences. The purpose of the study is to evaluate the efficacy of Rifaximin in the treatment of cirrhotic gastroesophageal variceal bleeding.

Conditions

• Cirrhosis
• Esophageal and Gastric Varices
• Gastrointestinal Hemorrhage

Interventions

Type	Name	Description
DRUG	Rifaximin	ALFA WASSERMANN S.p.A.

Timeline

• Start date: 2016-11-01
• Primary completion: 2017-10-01
• Completion: 2018-04-01
• First posted: 2016-11-16
• Last updated: 2016-11-16

Locations

1 site across 1 country: China